Author(s):
Chetan Suvarna, Ipseeta Ray Mohanty, Sandeep Rai, Mariya Khan
Email(s):
ipseetamohanty@yahoo.co.in
DOI:
10.52711/0974-360X.2026.00452 
Address:
Chetan Suvarna1, Ipseeta Ray Mohanty1, Sandeep Rai2, Mariya Khan1
1Department of Pharmacology, MGM Medical College (MGMIHS), Kamothe, Navi Mumbai, Maharashtra 410209, India.
2Department of Medicine, MGM Medical College (MGMIHS), Kamothe, Navi Mumbai, Maharashtra 410209, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 7,
Year - 2026
ABSTRACT:
This study analyzes prescribing trends of antidiabetic medications in overweight and obese patients with type 2 diabetes mellitus (T2DM), emphasizing rational drug use and individualized treatment. A total of 200 prescriptions were reviewed, revealing an average of 2.23 drugs per prescription. Metformin was the most common monotherapy (62.22%), followed by sitagliptin (19.5%), glimepiride (8.69%), and dapagliflozin (8.69%). Combination therapy was frequent, particularly sitagliptin with metformin (29.4%) and vildagliptin with metformin (24.7%). In advanced cases, triple or quadruple therapy included agents like dapagliflozin, voglibose, and glimepiride. Additionally, the study assessed body composition and glycemic control over three months in newly diagnosed T2DM patients. Significant improvements were observed in body weight, BMI, visceral fat, skeletal muscle mass, and HbA1c levels. These findings underscore the value of weight-conscious, guideline-based prescribing to enhance metabolic control. The study supports the need for tailored therapies to achieve optimal outcomes in overweight and obese T2DM patients.
Cite this article:
Chetan Suvarna, Ipseeta Ray Mohanty, Sandeep Rai, Mariya Khan. Prescribing Pattern and Impact of Antidiabetic Drugs on Body Composition Indices among Obese or Overweight patients with Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2026;19(7):3181-8. doi: 10.52711/0974-360X.2026.00452
Cite(Electronic):
Chetan Suvarna, Ipseeta Ray Mohanty, Sandeep Rai, Mariya Khan. Prescribing Pattern and Impact of Antidiabetic Drugs on Body Composition Indices among Obese or Overweight patients with Type 2 Diabetes Mellitus. Research Journal of Pharmacy and Technology. 2026;19(7):3181-8. doi: 10.52711/0974-360X.2026.00452 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-7-39
REFERENCES:
1. Feng WH, Bi Y, Li P, Yin TT, Gao CX. et al Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: A randomized trial. Journal of Diabetes Investigation. 2019 Mar; 10(2): 399-407.
2. Agcakaya E, Mutlu HH, Erbakan A, Sargin M. Comparison of the impact of SGLT2-inhibitors and exenatide on body fat composition. J Coll Physicians Surg Pak. 2023 Mar 1; 33(3): 308-13.
3. Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D et. al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies- EASO can lead the way. Obesity facts. 2017 Oct 12; 10(5): 483-92.
4. Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020 Oct 9; 13: 3611-3616
5. Vasanthakumar J, Kambar S. Prevalence of obesity among type 2 diabetes mellitus patients in urban areas of Belagavi. Indian Journal of Health Sciences and Biomedical Research kleu. 2020 Jan 1; 13(1): 21-7.
6. World Health Organization. The WHO STEP wise approach to non-communicable disease risk factor surveillance. World Heal Organ 2017; 36: 1‑474.10
7. International Diabetes Institute/ Western Pacific World Health Organization/ International, Force A for the study of OIOT. The Asia‑Pacific perspective: redefining obesity and its treatment. Geneva, Switz. World Health Organisation 2000; 56
8. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, et. al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice. 2022 Jan 1; 183: 109119.
9. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian Journal of Ophthalmology. 2021 Nov; 69(11): 2932.
10. Islam Aovi F, Sayantan Halder S, Kamruzzaman M. A Study on The Prescribing Patterns of Dipeptidyl Peptidase 4 Inhibitors in A Multi-Disciplinary Hospital Complex Birdem, Bangladesh. International Journal of Advance and Review. 2016; 1(10). DOI:10.12890/2019_001207
11. Chew NW, Pan XH, Chong B, Chandramouli C, Muthiah M, et. al. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Diabetes Research and Clinical Practice. 2024 May 1; 211: 111652.
12. Brunton LL, Hilal-Dandan R, Knollmann BC. As Bases Farmacológicas da Terapêutica de Goodman e Gilman-13. Artmed Editora. 2018 Dec 19.
13. Bonora E. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin‐based treatment on body weight. International Journal of Clinical Practice. 2007 Aug; 61:19-28.
14. Jha H, Khan TA, Khan N, Fatima G, DAS S. Analysis of Prescription Pattern of Anti-diabetic Medications in a Teaching Hospital in North India. Cureus. 2024 Jun 28; 16(6).
15. Bays HE, Chapman RH, Grandy S, SHIELD Investigators’ Group. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. International Journal of Clinical Practice. 2007 May; 61(5): 737-47.
16. Maiti R, Bhatia V, Padhy BM, Hota D. Essential medicines: an Indian perspective. Indian journal of community medicine: official publication of Indian Association of Preventive and Social Medicine. 2015 Oct; 40(4): 223.
17. Sarkar S, Srivastava V, Roy A, Mohanty M. Prescribing pattern of antidiabetic drugs amongst pre-obese diabetic patients in a tertiary care hospital. An observational study. Diabetes Obes Int J. 2019; 4(2): 2-10.
18. Mandal S, Maiti T, Das AK, Das A, Mandal A, Mandal et. al. Drug utilization study in patients with type 2 diabetes mellitus attending diabetes clinic of a tertiary care hospital in rural Bengal. Int J Basic Clin Pharmacol. 2016 Aug; 5(4): 1647-54.
19. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian journal of ophthalmology. 2021 Nov; 69(11): 2932.
20. Holst J. J., Vilsbøll T., Deacon C. F. The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology. 2009; 297(1-2): 127-136.
21. 0Holst J. J., Vilsbøll T., Deacon C. F. The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology. 2009; 297(1-2):127-136.
22. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycemic agents in type 2 diabetes mellitus. Drug Saf. 2007; 30(12): 1127-1142.
23. Borah M, Goswami RK. Sociodemographic and clinical characteristics of a diabetic population at a tertiary care center in Assam, India. Journal of Social Health and Diabetes. 2017 Jun; 5(01): 037-42.
24. Saber S, Haque MT, Alam MT, Hossain MM. Study on Socio-Demographic and Anthropometric Profile among Newly Detected Diabetic Patients Attending in a Tertiary Care Teaching Hospital, Dhaka, Bangladesh. European Journal of Medical and Health Sciences. 2021 Feb 10; 3(1): 150-3.
25. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag. 2012; 8: 463-72. doi: 10.2147/HIV.S33194. Pub 2012 Aug 15. Erratum in: Vasc Health Risk Manag. 2013; 9: 1. PMID: 23028231; PMCID: PMC3448454.
26. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C et. al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Annals of internal medicine. 2016 Jun 7;164(11):740-51.
27. Mushtaq S, Mayee K, Amreen S, Satyanarayana V, Yerramilli A, et. al. A study on the current prescribing patterns of dipeptidyl peptidase 4 inhibitors in a multi-speciality hospital outpatient setting. Asian J Pharm Clin Res. 2014; 7(2): 134-6.
28. Bramante CT, Lee CJ, Gudzune KA. Treatment of Obesity in Patients with Diabetes. Diabetes Spectr. 2017 Nov; 30(4): 237-243. doi: 10.2337/ds17-0030. PMID: 29151713; PMCID: PMC5687113.